Large scale and clinical grade purification of syndecan-1+ malignant plasma cells.
For cancer immunotherapy, it is usually necessary to obtain a large number of tumor cells from patients. We have previously reported that syndecan-I is present only on malignant plasma cells in samples from patients with multiple myelomatosis. We report here that this antigen is cleaved by chymopapain. This makes it possible to develop a rapid and clinical grade procedure to purify large numbers of myeloma cells using anti-syndecan-1 mAb, magnetic beads and chymopapain.
Sun
R X
RX
Unit for Cellular Therapy, 3 Hôpital St. Eloi, Montpellier, France.
Lu
Z Y
ZY
Wijdenes
J
J
Brochier
J
J
Hertog
C
C
Rossi
J F
JF
Klein
B
B
D002917:Chymopapain; D006801:Humans; D018189:Immunomagnetic Separation / Q000379:methods*; D008562:Membrane Glycoproteins; D009101:Multiple Myeloma / Q000473:pathology*; D010950:Plasma Cells / Q000276:immunology / Q000473:pathology*; D011509:Proteoglycans; D053668:Syndecan-1; D053667:Syndecans
D008562:Membrane Glycoproteins; D011509:Proteoglycans; C508241:SDC1 protein, human; D053668:Syndecan-1; D053667:Syndecans; D002917:Chymopapain